Acromegaly - Pipeline Review, H2 2020
Acromegaly - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acromegaly - Pipeline Review, H2 2020, provides an overview of the Acromegaly (Hormonal Disorders) pipeline landscape.
Acromegaly is a hormonal disorder that develops when pituitary gland produces too much growth hormone during adulthood. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth and sleep apnea. Treatment includes surgery, dopamine agonists and growth hormone antagonists.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acromegaly - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Acromegaly (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acromegaly (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 7, 4, 4, 3 and 1 respectively.
Acromegaly (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acromegaly - Pipeline Review, H2 2020, provides an overview of the Acromegaly (Hormonal Disorders) pipeline landscape.
Acromegaly is a hormonal disorder that develops when pituitary gland produces too much growth hormone during adulthood. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth and sleep apnea. Treatment includes surgery, dopamine agonists and growth hormone antagonists.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acromegaly - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Acromegaly (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acromegaly (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 7, 4, 4, 3 and 1 respectively.
Acromegaly (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Acromegaly (Hormonal Disorders).
- The pipeline guide reviews pipeline therapeutics for Acromegaly (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acromegaly (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acromegaly (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acromegaly (Hormonal Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acromegaly (Hormonal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acromegaly (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Acromegaly - Overview
Acromegaly - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Acromegaly - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Acromegaly - Companies Involved in Therapeutics Development
Antisense Therapeutics Ltd
Aquestive Therapeutics Inc
Ascil Proyectos SL
Auritec Pharmaceuticals Inc
Camurus AB
Chiasma Inc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Dauntless Pharmaceuticals Inc
DexTech Medical AB
Enesi Pharma Ltd
Foresee Pharmaceuticals Co Ltd
GeneScience Pharmaceuticals Co Ltd
GlyTech Inc
Ionis Pharmaceuticals Inc
Italfarmaco SpA
OPKO Health Inc
Pharmathen Global BV
Strongbridge Biopharma plc
Acromegaly - Drug Profiles
atesidorsen sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DP-2018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FP-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-GHRLRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ITF-2984 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOD-12014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate microspheres - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide LA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide LA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
paltusotine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Somadex - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide IR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Acromegaly - Dormant Projects
Acromegaly - Discontinued Products
Acromegaly - Product Development Milestones
Featured News & Press Releases
Sep 04, 2020: Crinetics Pharmaceuticals provides new data from Paltusotine and ACTH antagonist development programs at European Congress of Endocrinology
Aug 31, 2020: Chiasma announces U.S. commercial launch and availability of MYCAPSSA, the first and only oral somatostatin analog for patients with acromegaly
Aug 17, 2020: Chiasma announces publication of pivotal data from the phase 3 CHIASMA OPTIMAL clinical trial in the journal of Clinical Endocrinology & Metabolism
Jul 27, 2020: Chiasma announces 48-week safety and efficacy data from the open-label extension study of its CHIASMA OPTIMAL phase 3 trial evaluating MYCAPSSA in patients with acromegaly
Jul 08, 2020: Crinetics Pharmaceuticals receives orphan drug designation for Paltusotine for the treatment of acromegaly
Jul 02, 2020: Camargo client Chiasma receives FDA approval for first and only oral somatostatin analog for long-term maintenance treatment of acromegaly
Jun 26, 2020: Chiasma announces FDA approval of MYCAPSSA (Octreotide) capsules, the first and only oral somatostatin analog
Jun 11, 2020: Crinetics Pharmaceuticals confirms completion for half of the enrolled patients in the ongoing phase 2 ACROBAT edge clinical trial for Paltusotine
Apr 06, 2020: Crinetics Pharmaceuticals reports positive interim results for the ACROBAT Edge phase 2 trial of Paltusotine (CRN00808) in acromegaly patients and provides corporate update
Jan 13, 2020: Chiasma announces FDA acceptance of MYCAPSSA New Drug Application Resubmission
Aug 26, 2019: Acromegaly early access program - status update
Jul 23, 2019: Chiasma announces positive phase 3 top-line results from CHIASMA OPTIMAL clinical trial of Mycapssa for the maintenance treatment of adults with Acromegaly
Jun 27, 2019: Chiasma provides update on ongoing Mycapssa phase 3 clinical trials
Jun 20, 2019: Camurus Receives IND Acceptance From the FDA to Enter Phase 3 with CAM2029 for Treatment of Acromegaly
Jun 05, 2019: Chiasma strengthens leadership team ahead of anticipated commercial availability of Mycapssa
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Acromegaly - Overview
Acromegaly - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Acromegaly - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Acromegaly - Companies Involved in Therapeutics Development
Antisense Therapeutics Ltd
Aquestive Therapeutics Inc
Ascil Proyectos SL
Auritec Pharmaceuticals Inc
Camurus AB
Chiasma Inc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Dauntless Pharmaceuticals Inc
DexTech Medical AB
Enesi Pharma Ltd
Foresee Pharmaceuticals Co Ltd
GeneScience Pharmaceuticals Co Ltd
GlyTech Inc
Ionis Pharmaceuticals Inc
Italfarmaco SpA
OPKO Health Inc
Pharmathen Global BV
Strongbridge Biopharma plc
Acromegaly - Drug Profiles
atesidorsen sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DP-2018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FP-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-GHRLRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ITF-2984 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOD-12014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide acetate microspheres - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide LA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide LA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
octreotide SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
paltusotine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Somadex - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veldoreotide IR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Acromegaly - Dormant Projects
Acromegaly - Discontinued Products
Acromegaly - Product Development Milestones
Featured News & Press Releases
Sep 04, 2020: Crinetics Pharmaceuticals provides new data from Paltusotine and ACTH antagonist development programs at European Congress of Endocrinology
Aug 31, 2020: Chiasma announces U.S. commercial launch and availability of MYCAPSSA, the first and only oral somatostatin analog for patients with acromegaly
Aug 17, 2020: Chiasma announces publication of pivotal data from the phase 3 CHIASMA OPTIMAL clinical trial in the journal of Clinical Endocrinology & Metabolism
Jul 27, 2020: Chiasma announces 48-week safety and efficacy data from the open-label extension study of its CHIASMA OPTIMAL phase 3 trial evaluating MYCAPSSA in patients with acromegaly
Jul 08, 2020: Crinetics Pharmaceuticals receives orphan drug designation for Paltusotine for the treatment of acromegaly
Jul 02, 2020: Camargo client Chiasma receives FDA approval for first and only oral somatostatin analog for long-term maintenance treatment of acromegaly
Jun 26, 2020: Chiasma announces FDA approval of MYCAPSSA (Octreotide) capsules, the first and only oral somatostatin analog
Jun 11, 2020: Crinetics Pharmaceuticals confirms completion for half of the enrolled patients in the ongoing phase 2 ACROBAT edge clinical trial for Paltusotine
Apr 06, 2020: Crinetics Pharmaceuticals reports positive interim results for the ACROBAT Edge phase 2 trial of Paltusotine (CRN00808) in acromegaly patients and provides corporate update
Jan 13, 2020: Chiasma announces FDA acceptance of MYCAPSSA New Drug Application Resubmission
Aug 26, 2019: Acromegaly early access program - status update
Jul 23, 2019: Chiasma announces positive phase 3 top-line results from CHIASMA OPTIMAL clinical trial of Mycapssa for the maintenance treatment of adults with Acromegaly
Jun 27, 2019: Chiasma provides update on ongoing Mycapssa phase 3 clinical trials
Jun 20, 2019: Camurus Receives IND Acceptance From the FDA to Enter Phase 3 with CAM2029 for Treatment of Acromegaly
Jun 05, 2019: Chiasma strengthens leadership team ahead of anticipated commercial availability of Mycapssa
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Acromegaly, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Acromegaly - Pipeline by Antisense Therapeutics Ltd, H2 2020
Acromegaly - Pipeline by Aquestive Therapeutics Inc, H2 2020
Acromegaly - Pipeline by Ascil Proyectos SL, H2 2020
Acromegaly - Pipeline by Auritec Pharmaceuticals Inc, H2 2020
Acromegaly - Pipeline by Camurus AB, H2 2020
Acromegaly - Pipeline by Chiasma Inc, H2 2020
Acromegaly - Pipeline by Crinetics Pharmaceuticals Inc, H2 2020
Acromegaly - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2020
Acromegaly - Pipeline by Dauntless Pharmaceuticals Inc, H2 2020
Acromegaly - Pipeline by DexTech Medical AB, H2 2020
Acromegaly - Pipeline by Enesi Pharma Ltd, H2 2020
Acromegaly - Pipeline by Foresee Pharmaceuticals Co Ltd, H2 2020
Acromegaly - Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2020
Acromegaly - Pipeline by GlyTech Inc, H2 2020
Acromegaly - Pipeline by Ionis Pharmaceuticals Inc, H2 2020
Acromegaly - Pipeline by Italfarmaco SpA, H2 2020
Acromegaly - Pipeline by OPKO Health Inc, H2 2020
Acromegaly - Pipeline by Pharmathen Global BV, H2 2020
Acromegaly - Pipeline by Strongbridge Biopharma plc, H2 2020
Acromegaly - Dormant Projects, H2 2020
Acromegaly - Discontinued Products, H2 2020
Number of Products under Development for Acromegaly, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Acromegaly - Pipeline by Antisense Therapeutics Ltd, H2 2020
Acromegaly - Pipeline by Aquestive Therapeutics Inc, H2 2020
Acromegaly - Pipeline by Ascil Proyectos SL, H2 2020
Acromegaly - Pipeline by Auritec Pharmaceuticals Inc, H2 2020
Acromegaly - Pipeline by Camurus AB, H2 2020
Acromegaly - Pipeline by Chiasma Inc, H2 2020
Acromegaly - Pipeline by Crinetics Pharmaceuticals Inc, H2 2020
Acromegaly - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2020
Acromegaly - Pipeline by Dauntless Pharmaceuticals Inc, H2 2020
Acromegaly - Pipeline by DexTech Medical AB, H2 2020
Acromegaly - Pipeline by Enesi Pharma Ltd, H2 2020
Acromegaly - Pipeline by Foresee Pharmaceuticals Co Ltd, H2 2020
Acromegaly - Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2020
Acromegaly - Pipeline by GlyTech Inc, H2 2020
Acromegaly - Pipeline by Ionis Pharmaceuticals Inc, H2 2020
Acromegaly - Pipeline by Italfarmaco SpA, H2 2020
Acromegaly - Pipeline by OPKO Health Inc, H2 2020
Acromegaly - Pipeline by Pharmathen Global BV, H2 2020
Acromegaly - Pipeline by Strongbridge Biopharma plc, H2 2020
Acromegaly - Dormant Projects, H2 2020
Acromegaly - Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development for Acromegaly, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
COMPANIES MENTIONED
Antisense Therapeutics Ltd
Aquestive Therapeutics Inc
Ascil Proyectos SL
Auritec Pharmaceuticals Inc
Camurus AB
Chiasma Inc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Dauntless Pharmaceuticals Inc
DexTech Medical AB
Enesi Pharma Ltd
Foresee Pharmaceuticals Co Ltd
GeneScience Pharmaceuticals Co Ltd
GlyTech Inc
Ionis Pharmaceuticals Inc
Italfarmaco SpA
OPKO Health Inc
Pharmathen Global BV
Strongbridge Biopharma plc
Number of Products under Development for Acromegaly, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
COMPANIES MENTIONED
Antisense Therapeutics Ltd
Aquestive Therapeutics Inc
Ascil Proyectos SL
Auritec Pharmaceuticals Inc
Camurus AB
Chiasma Inc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Dauntless Pharmaceuticals Inc
DexTech Medical AB
Enesi Pharma Ltd
Foresee Pharmaceuticals Co Ltd
GeneScience Pharmaceuticals Co Ltd
GlyTech Inc
Ionis Pharmaceuticals Inc
Italfarmaco SpA
OPKO Health Inc
Pharmathen Global BV
Strongbridge Biopharma plc
